Abiopharma

🔍 Novo Holdings A/S (Executive)

Company: Avalyn Pharma Inc. (AVLN)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Acquired 3,327,734 shares of Voting Common Stock (Direct)
  Date: 2026-05-01 | Code: C | equity_swap_involved: 0 | shares_owned_after: 3,327,734.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 555,555 shares of Voting Common Stock at $18.0 per share (Direct)
  Date: 2026-05-01 | Code: P | equity_swap_involved: 0 | shares_owned_after: 3,883,289.00 | transaction_form_type: 4
• Sold 935,466 shares of Series A Preferred Stock (Derivative)
  Date: 2026-05-01 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1
• Sold 103,232 shares of Series B Preferred Stock (Derivative)
  Date: 2026-05-01 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1
• Sold 1,345,997 shares of Series C-1 Preferred Stock (Derivative)
  Date: 2026-05-01 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1
• Sold 290,390 shares of Series C-2 Preferred Stock (Derivative)
  Date: 2026-05-01 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1
• Sold 652,649 shares of Series D Preferred Stock (Derivative)
  Date: 2026-05-01 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1

Footnotes:

• F1: The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date.